Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma

The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Cucci, Marie Angèle, Grattarola, Margherita, Monge, Chiara, Roetto, Antonella, Barrera, Giuseppina, Caputo, Emilia, Dianzani, Chiara, Pizzimenti, Stefania
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294952/
https://www.ncbi.nlm.nih.gov/pubmed/37372043
http://dx.doi.org/10.3390/antiox12061313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294952/
https://www.ncbi.nlm.nih.gov/pubmed/37372043
http://dx.doi.org/10.3390/antiox12061313

Ejemplares similares